Farnesyltransferase inhibitors and anti-Ras therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Mutant Ras proteins require posttranslational farnesylation for biological activity and membrane localization.
• Farnesylation is catalyzed by farnesyl-protein transferase (FPTase), a crucial enzyme in Ras signaling pathways.
• Ras signaling controls cell growth and differentiation, and its dysregulation is implicated in cancer.

Purpose of the Study:

• To investigate farnesyl-protein transferase (FPTase) inhibitors as potential anticancer agents.
• To determine if FPTase inhibition can block Ras-induced cell transformation and proliferation.
• To evaluate the efficacy and specificity of FPTase inhibitors against Ras-transformed cells.

Main Methods:

• Synthesis and screening of various natural products and synthetic compounds as FPTase inhibitors.
• In vitro assays to measure inhibition of Ras protein farnesylation.
• Cell culture studies to assess antiproliferative activity and morphological changes in Ras-transformed cells.
• Tumor colony-forming assays and animal tumor models to evaluate in vivo efficacy and toxicity.

Main Results:

• Numerous compounds were identified that inhibit Ras protein farnesylation in vitro.
• Some inhibitors demonstrated antiproliferative effects, reversed morphological transformation, and inhibited colony formation of Ras-transformed cells.
• Inhibitors specifically targeted Ras-transformed cells, showing no effect on cells transformed by Raf or Mos oncoproteins.
• FPTase inhibitors exhibited efficacy and low toxicity in an animal tumor model.

Conclusions:

• Farnesyl-protein transferase (FPTase) is a viable target for anticancer drug development.
• Specific FPTase inhibitors can effectively block Ras-driven oncogenesis.
• FPTase inhibitors hold potential for the treatment of cancers driven by Ras mutations.